Leerink Partners Raises Crinetics Pharmaceuticals' Target Price to $88

Summary

Leerink Partners has raised its price target for Crinetics Pharmaceuticals (NASDAQ:CRNX) from $80.00 to $88.00, maintaining an ‘outperform’ rating. This new target suggests a potential upside of 91.68% from the stock’s previous close. Other analysts have also adjusted their targets, with Robert W. Baird setting it at $62.00 and JMP Securities at $143.00. Crinetics Pharmaceuticals reported a quarterly revenue increase of 158.4% year-over-year, despite missing earnings estimates. The stock currently has a consensus rating of ‘Moderate Buy’ with an average target price of $72.78.Market Beat

Impact Analysis

So basically, Leerink Partners is betting on Crinetics Pharmaceuticals’ recent FDA approval of Palsonify to drive significant growth. The price target bump to $88 reflects optimism about the drug’s market potential, especially given its unique position as the first daily oral treatment for acromegaly. The timing is interesting—right after the FDA nod, which suggests Leerink sees this as a pivotal moment for Crinetics. The revenue jump of 158.4% year-over-year is impressive, but missing earnings estimates could be a concern if costs aren’t managed well. The varied analyst targets—from $36 to $143—highlight uncertainty in execution risk and market adoption. The market might be underestimating the potential impact of Palsonify, especially if it becomes the standard-of-care. Watch for how competitors respond and any shifts in insurance coverage that could affect pricing power.Market Beat+ 3